Keynote: Vicki Seyfert-Margolis, US Food and Drug Administration
"How communities can work to achieve change in drug discovery"
APRIL 16, 2011 -- PART 3: COMMITMENTS FOR 2011
The final part of the Congress will connect the strands of day 1 and consider what can be done. There will be a keynote on how communities can effect change followed by reports from the five Communities of Interest, concluding with a session where attendees will be asked what they want to do, or will do, as a follow-up to the Congress. Attendees will film each other outlining their commitments as part of both the larger Commons community and as part of their Community of Interest. There will then be a closing keynote including a report on the large "game changer" by Stephen Friend.
At the conclusion of the Congress attendees will understand how their own work connects to the greater movement of change in how we must approach biology and how biology relates to health care. Participants will be challenged to articulate how their work from the previous day and over the next year might lead to more sharing, better resource allocation, and faster progress. Participants will have established a set of communities ready to do active work.
Vicki L. Seyfert-Margolis
Vicki Seyfert-Margolis, Ph.D., serves as the Senior Science Advisor to the FDA's Chief Scientist in the mission of upgrading science, with a focus on bioinformatics and advancing regulatory science. She has most recently been Chief Scientific Officer at Immune Tolerance Network, a non-profit consortium of researchers seeking new treatments for diseases of the immune system; and an Adjunct Associate Professor with the Department of Medicine at the University of California - San Francisco.
Prior to that, Seyfert-Margolis was a program director in innovative scientific research at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Seyfert-Margolis research interests are: Immunology, biomarker development, advancing scientific computing environment/high density data, health information technology, validation and standards development.